Difference between revisions of "Part:BBa K1202107"
Line 1: | Line 1: | ||
− | |||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K1202107 short</partinfo> | <partinfo>BBa_K1202107 short</partinfo> | ||
− | + | The general attitude to our parts is to designate alternative parts. For cancer killing mechanism, we searched through literature and found E4orf4 peptide. This derivative prospective cancer drug, like apoptin, induces apoptosis in cancer cells, selectively. Moreover, in literature and, of course iGEM, TAT-E4orf4 combination is completely novel. | |
− | + | ||
− | + | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here |
Latest revision as of 00:45, 5 October 2013
TAT-E4-orf4: Cancer killing peptide
The general attitude to our parts is to designate alternative parts. For cancer killing mechanism, we searched through literature and found E4orf4 peptide. This derivative prospective cancer drug, like apoptin, induces apoptosis in cancer cells, selectively. Moreover, in literature and, of course iGEM, TAT-E4orf4 combination is completely novel.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 7
Illegal NheI site found at 30 - 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 158
Illegal NgoMIV site found at 167 - 1000COMPATIBLE WITH RFC[1000]